Translational Development Acquisition Corp. Ordinary Shares Cash Flow Conversion Efficiency
Translational Development Acquisition Corp. Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) has a cash flow conversion efficiency ratio of -0.002x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-338.75K) by net assets ($149.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
Cash flow conversion efficiency of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Translational Development Acquisition Co for real-time trading data and today's change.
Translational Development Acquisition Corp. Ordinary Shares Cash Flow Conversion Ratio Explained
Translational Development Acquisition Corp. Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Translational Development Acquisition Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Translational Development Acquisition Corp. Ordinary Shares ranked by their cash flow conversion efficiency. Also see TDAC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xsolla SPAC 1 Class A Ordinary Shares
NASDAQ:XSLL
|
-0.001x |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
0.057x |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
0.181x |
|
OP Bancorp
NASDAQ:OPBK
|
0.105x |
|
Alta Equipment Group Inc
NYSE:ALTG
|
-0.735x |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
0.151x |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
N/A |
|
Coca Cola HBC AG
LSE:CCH
|
0.137x |
Annual Cash Flow Conversion Efficiency for Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. Review TDAC financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $175.12 Million | $-608.39K | -0.003x | +31.14% |
| 2024-12-31 | $168.75 Million | $-851.45K | -0.005x | -1355.59% |
| 2023-12-31 | $-507.66K | $-204.00 | 0.000x | -99.99% |
| 2022-12-31 | $-22.11K | $-97.16K | 4.395x | -- |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.